BUS 6320 V DBR1

2

Global Strategic Management BUS 6320 Unit V Discussion Board Reply 1

Reply to classmate below, at least 300 words and APA formattingTop of Form

Top of Form

Defense of Purdue Pharma and Strategic Implications

As defense counsel for Purdue Pharma and the Sackler family regarding the events detailed in MiniCase 12, it is imperative to objectively analyze the firm's strategic intent and the regulatory environment in which it operated. The key elements of this case center on Purdue Pharma’s development and commercialization of OxyContin. The firm utilized a breakthrough time-controlled release formulation, initially developed for MS Contin, and combined it with oxycodone. The FDA approved this specialty pharmaceutical in 1995 for moderate to severe pain, granting a label that suggested the delayed absorption mechanism reduced its abuse liability (Rothaermel, 2024). Purdue Pharma subsequently launched an aggressive, highly successful marketing campaign that shifted the national medical narrative toward treating pain as the "fifth vital sign," resulting in unprecedented financial growth before the tragic realities of widespread opioid abuse led to thousands of lawsuits and the company's eventual bankruptcy.

From a defense perspective, Purdue Pharma’s initial corporate strategy was legally sound and focused on a genuine medical need: alleviating chronic, debilitating pain. The company operated entirely within the bounds of FDA approvals. The core issue was not the innovation of the drug itself, but rather a systemic breakdown in downstream healthcare utilization management. When patients were prescribed these highly potent specialty pharmaceuticals, the responsibility for monitoring dosage, duration, and patient behavior ultimately fell to independent medical professionals. Purdue Pharma manufactured a legal, highly regulated product; the subsequent misuse and overprescription by independent physicians highlight a failure in clinical care coordination rather than a criminal corporate strategy.

Analyzing this case is vital for formulating future corporate strategy, particularly in highly regulated industries. It demonstrates that a firm's strategy cannot exist in a vacuum. Formulating a sustainable corporate strategy requires anticipating how a product will be utilized in the real world and establishing proactive risk-mitigation protocols. While Purdue successfully executed a corporate strategy of market penetration and aggressive sales growth, the case illustrates the catastrophic risks of scaling a product without simultaneously advocating for stringent healthcare utilization management and ethical compliance guardrails. For future strategists, Purdue Pharma serves as a stark reminder that long-term corporate success requires balancing rapid innovation with a profound responsibility toward public health outcomes and ecosystem stability (Rothaermel, 2024).

Reference

Rothaermel, F. T. (2024).  Strategic management (6th ed.). McGraw Hill.

Bottom of Form